Prior Authorization of Drugs – Beginning 1/1/2015 C.R.S. 10-16-124.5 and C.C.R. 4-2-49

Beginning on January 1, 2015, all carriers are required to utilize the uniform prior authorization process established by regulation 4-2-49.

A prior authorization process for a drug benefit shall:

- 1. Be made available electronically to the prescribing provider;
- 2. Make the following **information available and accessible in a centralized location** on the carrier's or its designated pharmacy benefit management firm's website:
 - a. The **prior authorization requirements and restrictions**, including, but not limited to:
 - (1) The prescribing provider's obligation to respond to requests for additional information; and
 - (2) When requests will be deemed "approved" or "denied";
 - An alphabetical list of drugs, including both brand name and scientific name, that require prior authorization, including the clinical criteria and supporting references that will be used in making a prior authorization determination;
 - Written clinical criteria that include the criteria for reauthorization of a
 previously approved drug, if applicable, after the previous approval period has
 expired; and
 - d. The **standard form** for prior authorization for a drug benefit.
- 3. Include **evidence-based guidelines** to be used by the carrier when making prior authorization determinations;
- 4. **Allow for, but not require, the electronic submission** of prior authorization requests for a drug benefit to the carrier.

Timely processing of the prior authorization:

A. Urgent prior authorization request

- 1. A carrier shall process and provide notification of approval or denial to the patient, prescribing provider, and dispensing pharmacy within one (1) business day of receiving an urgent prior authorization request. Carriers shall include appropriate information on the expedited appeals process related to urgent care situations, as found in § 10-16-113, C.R.S., and associated regulations, with any denial of an urgent prior authorization request.
 - a. If additional information is required to process an urgent prior authorization request, the carrier must advise the prescribing provider of any and all information needed within one (1) business day of receiving the request.
 - b. If additional information is required to process an urgent prior authorization request, the prescribing provider shall submit the information requested

- by the carrier within two (2) business days of receiving such a request from the carrier.
- c. Once the requested additional information is received, the carrier shall make a determination within one (1) business day of receipt of the information.
- d. If the additional information requested from the prescribing provider is not received within two (2) business days of the prescribing provider receiving such a request, the request shall be deemed denied. The carrier shall provide the patient, prescribing provider, and the dispensing pharmacy with a confirmation of the denial within one (1) business day of the date the request was deemed denied.
- 2. If a carrier does not request additional information or provide notification of approval or denial within one (1) business day the request shall be deemed approved. The carrier shall provide the patient, prescribing provider, and the dispensing pharmacy with a confirmation of the deemed approval within one (1) business day of date the request was deemed approved.

B. Non-urgent prior authorization requests

- 1. A carrier shall process and provide notification of approval or denial to the patient, prescribing provider, and dispensing pharmacy within two (2) business days of receiving a non-urgent prior authorization request that has been submitted through the carrier's electronic pre-authorization system.
 - a. If additional information is required, the carrier must advise the prescribing provider of any and all information needed within two (2) business days of receiving the non-urgent prior authorization request.
 - b. If additional information is required to process a non-urgent prior authorization request, the **prescribing provider shall submit the information requested by the carrier within two (2) business days** of receiving such a request from the carrier.
 - c. Once the requested additional information is received, the carrier shall make a determination within two (2) business days of receipt for a non-urgent prior authorization request that was submitted through the carrier's electronic pre-authorization system, or three (3) business days of receipt for a non-urgent prior authorization request that has been submitted via facsimile, electronic mail, or verbally with associated written confirmation.
 - d. If the additional information requested from the prescribing provider is not received within two (2) business days of the prescribing provider receiving such a request, the request shall be deemed denied. The carrier shall provide the patient, prescribing provider, and the dispensing pharmacy with a confirmation of the denial within two (2) business days of the date the request was deemed denied.
- 2. A carrier shall process and provide notification of approval or denial to the patient, prescribing provider, and dispensing pharmacy within three (3) business days of receiving a non-urgent prior authorization request that has

- been **submitted via facsimile**, **electronic mail**, **or verbally** with associated written confirmation.
- 3. If a carrier does not request additional information or provide notification of approval or denial within:
 - a. Two (2) business days of the receipt of an electronically filed non-urgent prior authorization request, the request shall be deemed approved. The carrier shall provide the patient, prescribing provider, and the dispensing pharmacy with a confirmation of the deemed approval within two (2) business days of the date the request was deemed approved; or
 - b. Three (3) business days of the receipt of a non-urgent prior authorization request that has been submitted via facsimile, electronic mail, or verbally with associated written confirmation, the request shall be deemed approved. The carrier shall provide the patient, prescribing provider, and the dispensing pharmacy with a confirmation of the deemed approval within two (2) business days of the date the request was deemed approved.

Carrier's/PBM's prior authorization notification should include:

- 1. A **unique prior authorization number** attributable only to that drug benefit approval request;
- Specifications for the particular approved drug benefit, and the source and date of the clinical criteria used to make the determination for each particular drug:
- 3. The **next date for review** of the approved drug benefit; and
- 4. A **link to the current criteria** that will need to be submitted in order to reapprove the current prior authorization.

Other information:

- 1. When notifying a prescribing provider of a prior authorization denial, a carrier shall include a notice to the prescribing provider, and dispensing pharmacy, if provided, that the covered person has the right to appeal the adverse determination pursuant to §§ 10-16-113 and 10-16-113.5, C.R.S.
- 2. A prior authorization approval is valid for at least one hundred eighty (180) days after the date of approval.
- 3. If a prior authorization request is submitted electronically, verbally, via facsimile, or electronic mail, the response to that request shall be made through the same medium, or in a manner specifically requested by the provider.

Beginning on January 1, 2015, all carriers shall utilize the uniform prior authorization form below.

[CARRIER LOGO] [CARRIER NAME]

UNIFORM PHARMACY PRIOR AUTHORIZATION REQUEST FORM CONTAINS CONFIDENTIAL PATIENT INFORMATION

Complete this form in its entirety and send to:

[CARRIER OR PHARMACY BENEFIT MANAGEMENT FIRM CONTACT INFORMATION]

Urgent 1	□ Non-Urgent
Requested Drug Name:	
tient Information:	Prescribing Provider Information:
Patient Name:	Prescriber Name:
Member/Subscriber Number:	Prescriber Fax:
Policy/Group Number:	Prescriber Phone:
Patient Date of Birth (MM/DD/YYYY):	Prescriber Pager:
Patient Address:	Prescriber Address:
alient Address.	1 resoluci Address.
Patient Phone:	Prescriber Office Contact:
Patient Email Address:	Prescriber NPI:
	Prescriber DEA:
Prescription Date:	Prescriber Tax ID:
	Specialty/Facility Name (If applicable):
	Prescriber Email Address:
	Donofite
or Authorization Request for Drug E Patient Diagnosis and ICD Diagnostic Code(s): Drug(s) Requested (with J-Code, if applicable):	3enefit: □ New Request □ Reauthorization
Patient Diagnosis and ICD Diagnostic Code(s): Drug(s) Requested (with J-Code, if applicable):	New Request Reauthorization
Patient Diagnosis and ICD Diagnostic Code(s):	New Request Reauthorization
Patient Diagnosis and ICD Diagnostic Code(s): Drug(s) Requested (with J-Code, if applicable): Strength/Route/Frequency:	New Request Reauthorization
Patient Diagnosis and ICD Diagnostic Code(s): Drug(s) Requested (with J-Code, if applicable): Strength/Route/Frequency: Unit/Volume of Named Drug(s): Start Date and Length of Therapy:	ity, home health, etc.) including name, Type 2 NPI (if applicable), address and
Patient Diagnosis and ICD Diagnostic Code(s): Drug(s) Requested (with J-Code, if applicable): Strength/Route/Frequency: Unit/Volume of Named Drug(s): Start Date and Length of Therapy: Location of Treatment: (e.g. provider office, facili D: Clinical Criteria for Approval, Including other Per Name(s), Duration, and Patient Response:	ity, home health, etc.) including name, Type 2 NPI (if applicable), address an
Patient Diagnosis and ICD Diagnostic Code(s): Drug(s) Requested (with J-Code, if applicable): Strength/Route/Frequency: Unit/Volume of Named Drug(s): Start Date and Length of Therapy: Location of Treatment: (e.g. provider office, facili D: Clinical Criteria for Approval, Including other Per Name(s), Duration, and Patient Response: ADD ADDITIONAL LINES AS NEEDED SO AS	ity, home health, etc.) including name, Type 2 NPI (if applicable), address and tinent Information to Support the Request, other Medications Tried, Their TO CONTAIN ALL APPROVAL CRITERIA]
Patient Diagnosis and ICD Diagnostic Code(s): Drug(s) Requested (with J-Code, if applicable): Strength/Route/Frequency: Unit/Volume of Named Drug(s): Start Date and Length of Therapy: Location of Treatment: (e.g. provider office, facili D: Clinical Criteria for Approval, Including other Per Name(s), Duration, and Patient Response: ADD ADDITIONAL LINES AS NEEDED SO AS For use in clinical trial? (If yes, provide trial name	ity, home health, etc.) including name, Type 2 NPI (if applicable), address and tinent Information to Support the Request, other Medications Tried, Their TO CONTAIN ALL APPROVAL CRITERIA] are and registration number):
Patient Diagnosis and ICD Diagnostic Code(s): Drug(s) Requested (with J-Code, if applicable): Strength/Route/Frequency: Jnit/Volume of Named Drug(s): Start Date and Length of Therapy: Location of Treatment: (e.g. provider office, facili D: Clinical Criteria for Approval, Including other Per Name(s), Duration, and Patient Response: ADD ADDITIONAL LINES AS NEEDED SO AS For use in clinical trial? (If yes, provide trial name Drug Name (Brand Name and Scientific Name)/s	ity, home health, etc.) including name, Type 2 NPI (if applicable), address and tinent Information to Support the Request, other Medications Tried, Their TO CONTAIN ALL APPROVAL CRITERIA] and registration number): Strength:
Patient Diagnosis and ICD Diagnostic Code(s): Drug(s) Requested (with J-Code, if applicable): Strength/Route/Frequency: Unit/Volume of Named Drug(s): Start Date and Length of Therapy: Location of Treatment: (e.g. provider office, facili D: Clinical Criteria for Approval, Including other Per Name(s), Duration, and Patient Response: ADD ADDITIONAL LINES AS NEEDED SO AS For use in clinical trial? (If yes, provide trial name Drug Name (Brand Name and Scientific Name)/Sose:	ity, home health, etc.) including name, Type 2 NPI (if applicable), address and tinent Information to Support the Request, other Medications Tried, Their TO CONTAIN ALL APPROVAL CRITERIA] a and registration number): Strength: Dute: Frequency:
Patient Diagnosis and ICD Diagnostic Code(s): Drug(s) Requested (with J-Code, if applicable): Strength/Route/Frequency: Unit/Volume of Named Drug(s): Start Date and Length of Therapy: Location of Treatment: (e.g. provider office, facili D: Clinical Criteria for Approval, Including other Per Name(s), Duration, and Patient Response: ADD ADDITIONAL LINES AS NEEDED SO AS For use in clinical trial? (If yes, provide trial name Drug Name (Brand Name and Scientific Name)/Spose: Ro	ity, home health, etc.) including name, Type 2 NPI (if applicable), address and tinent Information to Support the Request, other Medications Tried, Their TO CONTAIN ALL APPROVAL CRITERIA] be and registration number): Strength: Dute: Frequency:
Patient Diagnosis and ICD Diagnostic Code(s): Drug(s) Requested (with J-Code, if applicable): Strength/Route/Frequency: Unit/Volume of Named Drug(s): Start Date and Length of Therapy: Location of Treatment: (e.g. provider office, facili D: Clinical Criteria for Approval, Including other Per Name(s), Duration, and Patient Response: ADD ADDITIONAL LINES AS NEEDED SO AS For use in clinical trial? (If yes, provide trial name Drug Name (Brand Name and Scientific Name)/SOSSE: Quantity: Regulation of Provided Including Name (Brand Name and Scientific Name)/SOSSE: Quantity: No.	ity, home health, etc.) including name, Type 2 NPI (if applicable), address and tinent Information to Support the Request, other Medications Tried, Their TO CONTAIN ALL APPROVAL CRITERIA] a and registration number): Strength:
Patient Diagnosis and ICD Diagnostic Code(s): Drug(s) Requested (with J-Code, if applicable): Strength/Route/Frequency: Unit/Volume of Named Drug(s): Start Date and Length of Therapy: Location of Treatment: (e.g. provider office, facili D: Clinical Criteria for Approval, Including other Per Name(s), Duration, and Patient Response: ADD ADDITIONAL LINES AS NEEDED SO AS For use in clinical trial? (If yes, provide trial name Drug Name (Brand Name and Scientific Name)/S Dose: Quantity: Product will be delivered to:	ity, home health, etc.) including name, Type 2 NPI (if applicable), address and tinent Information to Support the Request, other Medications Tried, Their TO CONTAIN ALL APPROVAL CRITERIA] e and registration number): Strength: Dute: Frequency: Jumber of Refills: Home Physician Office Other: Date:
Patient Diagnosis and ICD Diagnostic Code(s): Drug(s) Requested (with J-Code, if applicable): Strength/Route/Frequency: Unit/Volume of Named Drug(s): Start Date and Length of Therapy: Location of Treatment: (e.g. provider office, facili D: Clinical Criteria for Approval, Including other Per Name(s), Duration, and Patient Response: ADD ADDITIONAL LINES AS NEEDED SO AS For use in clinical trial? (If yes, provide trial name Drug Name (Brand Name and Scientific Name)/S Dose: Quantity: Product will be delivered to: Patient's	ity, home health, etc.) including name, Type 2 NPI (if applicable), address and tinent Information to Support the Request, other Medications Tried, Their TO CONTAIN ALL APPROVAL CRITERIA] e and registration number): Strength: Dute: Frequency: Jumber of Refills: Home Physician Office Other: Date:

^{1.} A request for prior authorization that if determined in the time allowed for non-urgent requests could seriously jeopardize the life or health of the covered person or the ability of the covered person to regain maximum function, or subject the person to severe pain that cannot be adequately managed without the drug benefit contained in the prior authorization request